a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announces thatThe New England Journal of Medicine(NEJM) has published a peer-reviewed Letter to the Editor describing the PEMGARDA™ (pemivibart) immunobridging emergency use authori...
” saidCameron R. Wolfe, M.B.B.S., M.P.H., Professor of Medicine, Transplant Infectious Disease atDuke University School of Medicine. “I’m excited to have PEMGARDA as an additional COVID-19 preventive option for moderately to severely immunocompromised...